These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 30352608)

  • 21. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
    Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
    Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The use of PET/CT in radiotherapy of patients with non-small cell lung cancer].
    Lõcsei Z; Hideghéty K; Farkas R; Bellyei S; Sárosi V; Sebestyén K; Sebestyén Z; Kovács P; Mangel L
    Magy Onkol; 2011 Nov; 55(4):274-80. PubMed ID: 22128310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study.
    Møller DS; Nielsen TB; Brink C; Hoffmann L; Lutz CM; Drøgemüller Lund M; Hansen O; Schytte T; Khalil AA; Knap MM; Nyhus CH; Ottosson W; Sibolt P; Borissova S; Josipovic M; Persson G; Appelt AL
    Radiother Oncol; 2017 Aug; 124(2):311-317. PubMed ID: 28688525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
    Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
    Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
    Chin AL; Kumar KA; Guo HH; Maxim PG; Wakelee H; Neal JW; Diehn M; Loo BW; Gensheimer MF
    Clin Lung Cancer; 2018 Sep; 19(5):e581-e588. PubMed ID: 29759331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.
    Li XX; Liu NB; Zhu L; Yuan XK; Yang CW; Ren P; Gong LL; Zhao LJ; Xu WG; Wang P
    Br J Radiol; 2015 Jul; 88(1051):20140590. PubMed ID: 25939819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study.
    de Figueiredo BH; Antoine M; Trouette R; Lagarde P; Petit A; Lamare F; Hatt M; Fernandez P
    Radiat Oncol; 2014 Dec; 9():300. PubMed ID: 25534014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volumetric-modulated arc therapy (RapidArc) vs. conventional fixed-field intensity-modulated radiotherapy for ¹⁸F-FDG-PET-guided dose escalation in oropharyngeal cancer: a planning study.
    Teoh M; Beveridge S; Wood K; Whitaker S; Adams E; Rickard D; Jordan T; Nisbet A; Clark CH
    Med Dosim; 2013; 38(1):18-24. PubMed ID: 22841937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing.
    Feng M; Kong FM; Gross M; Fernando S; Hayman JA; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1228-34. PubMed ID: 19251094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
    Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
    Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost.
    Weiss E; Fatyga M; Wu Y; Dogan N; Balik S; Sleeman W; Hugo G
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):414-9. PubMed ID: 23523321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of dose painting of lung tumours using alanine/EPR dosimetry.
    Knudtsen IS; Svestad JG; Skaug Sande EP; Rekstad BL; Rødal J; van Elmpt W; Öllers M; Hole EO; Malinen E
    Phys Med Biol; 2016 Mar; 61(6):2243-54. PubMed ID: 26913997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
    Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
    Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.